Sign Up Today and Learn More About PAQ Therapeutics Stock
Invest in or calculate the value of your shares in PAQ Therapeutics or other pre-IPO companies through EquityZen's platform.
PAQ Therapeutics Stock
PAQ Therapeutics is a biotechnology company pioneering a new approach to restoring health and curing disease through autophagy.
About PAQ Therapeutics Stock
Founded
2020
Headquarters
Cambridge, MA, US
Industries
Software, Artificial Intelligence, Data and Analytics
PAQ Therapeutics Press Mentions
Stay in the know about the latest news on PAQ Therapeutics
Kras g12d proteolysis targeting chimeras
patents • Feb 01, 2026
KRAS Proteolysis Targeting Chimeras
patents • Feb 01, 2026
PAQ Therapeutics Raises Series B Extension; Brings Total Series B to $77M
finsmes • Jan 26, 2026
PAQ Therapeutics Announces Series B Extension, Bringing Total Series B Financing to $77 Million; First Patient Dosed in Phase 1 Trial of PT0511, a Pan-KRAS Degrader
vcaonline • Jan 24, 2026
PAQ Therapeutics Announces Series B Extension, Bringing Total Series B Financing to $77 Million; First Patient Dosed in Phase 1 Trial of PT0511, a Pan-KRAS Degrader
prnewswire • Jan 22, 2026
PAQ Therapeutics Management
Leadership team at PAQ Therapeutics
Chief Medical Officer
Andrew Krivoshik
Scientific Advisory Board Member
Piro Lito
Join now and verify your accreditation status to gain access to:
- PAQ Therapeutics Current Valuation
- PAQ Therapeutics Stock Price
- PAQ Therapeutics Management
- Available deals in PAQ Therapeutics and all other companies with relevant Deal Offering documents
- EquityZen's proprietary data and insights, which may include
- PAQ Therapeutics Cap Table and Funding History by Share Class and Liquidity Preferences
- PAQ Therapeutics Revenue and Financials
- PAQ Therapeutics Highlights
- PAQ Therapeutics Business Model
- PAQ Therapeutics Risk Factors
- PAQ Therapeutics Research Report from SACRA Research
Trading PAQ Therapeutics Stock
How to invest in PAQ Therapeutics stock?
Accredited investors can buy pre-IPO stock in companies like PAQ Therapeutics through EquityZen funds. These investments are made available by existing PAQ Therapeutics shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process here.
How to sell PAQ Therapeutics stock?
Shareholders can sell their PAQ Therapeutics stock through EquityZen's private company marketplace. EquityZen's network includes over 420K accredited investors interested in buying private company stock. Learn more about the easy and guided Shareholder process here.
If I invest, how do I exit my investment?
There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. More information on Express Deals can be found here and exit information can be found here.
Why choose EquityZen?
Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 51K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."